<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="832">
  <stage>Registered</stage>
  <submitdate>12/10/2005</submitdate>
  <approvaldate>14/10/2005</approvaldate>
  <actrnumber>ACTRN12605000641695</actrnumber>
  <trial_identification>
    <studytitle>Effectiveness of DPA in comparison to DHA in lowering plasma triglyceride levels and other cardiovascular risk factors</studytitle>
    <scientifictitle>A randomised trial to evaluate the effects of DPA supplementation in the treatment of hypertriglyceridemia to reduce the risk of cardiovascular disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Hypertriglyceridaemic subjects</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention is a dietary supplementation of docosapentaenoic acid (DPA) in comparison to docosahexaenoic acid (DHA) for 6 weeks duration in hypertriglyceridemic subjects to assess the efficacy of triglyceride lowering effect.</interventions>
    <comparator>Placebo controlled (sunola oil)</comparator>
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assess the ability of DPA to lower plasma triglyceride levels in people with elevated plasma triglyceride levels. </outcome>
      <timepoint>Fasting plasma triglycerides will be measured on two consecutive days at week 0 and then again at week 6 of intervention.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the ability of dietary DPA on platelet aggregation (whole blood agonist induced ex vivo aggregation).</outcome>
      <timepoint>At weeks 0 and 2 of intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects with hypertriglyceridemia.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed envelopes</concealment>
    <sequence>Computer software microsoft excel</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The study also contains a third Placebo group where the placebo is sunola oil which does not contain DPA and DHA</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Wollongong</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Meat &amp; Livestock Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>RMIT University</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barbara Meyer</name>
      <address>Department of Biomedical Science
University of Wollongong
Northfields Ave
Wollongong NSW 2522</address>
      <phone>+61 2 42213459</phone>
      <fax />
      <email>bmeyer@uow.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barbara Meyer</name>
      <address>Department of Biomedical Science
University of Wollongong
Northfields Ave
Wollongong NSW 2522</address>
      <phone>+61 2 42213459</phone>
      <fax />
      <email>bmeyer@uow.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>